Development of monoclonal antibodies to prevent and treat infections from Flaviviruses

Last update: Oct 29, 2026

Details

Location: EU 27
Contracting Authority: Horizon Europe (2021 - 2027)
Contracting Authority Type: Development Institution
Status: Open
Budget: EUR 37,300,000
Award ceiling: 10,000,000
Award floor: 9,000,000
Sector: Health, Research & Innovation
Eligible applicants: Unrestricted / Unspecified
Eligible nationalities: Afghanistan, Albania, Algeria, Angola, Argentina, Armenia, Aruba, Austria, Azerbaijan, Bangladesh, Belarus, Belgium, Belize, Benin, Bhutan, Bolivia, Bosnia and Herzegovina, Bulgaria, Burkina Faso, Burundi, Cambodia, Cameroon, Canada, Cape Verde, Central African Republic, Chad, Colombia, Comoros, Congo, Costa Rica, Cote d'Ivoire, Croatia, Cuba, Curaçao, Cyprus, Czech Republic, Dem. Rep. Congo, Denmark, Djibouti, Dominica, Commonwealth of, Dominican Republic, Ecuador, Egypt, El Salvador, Equatorial Guinea, Eritrea, Estonia, Eswatini (Swaziland), Ethiopia, Faroe Islands, Fiji, Finland, France, French Polynesia, French Southern Territory, Gabon, Gambia, Georgia, Germany, Ghana, Greece, Greenland, Grenada, Guatemala, Guinea, Guinea-Bissau, Guyana, Haiti, Honduras, Hungary, Iceland, Indonesia, Iran, Iraq, Ireland, Israel, Italy, Jamaica, Jordan, Kazakhstan, Kenya, Kiribati, Kosovo, Kyrgyzstan, Laos, Latvia, Lebanon, Lesotho, Liberia, Libya, Lithuania, Luxembourg, Madagascar, Malawi, Malaysia, Maldives, Mali, Malta, Marshall Islands, Mauritania, Mauritius, Micronesia, Moldova, Mongolia, Montenegro, Morocco, Mozambique, Myanmar, Namibia, Nepal, Netherlands, New Caledonia, New Zealand, Nicaragua, Niger, Nigeria, Niue, North Korea, North Macedonia, Norway, Pakistan, Palau, Palestine / West Bank & Gaza, Papua New Guinea, Paraguay, Peru, Philippines, Poland, Portugal, Romania, Rwanda, Saint Lucia, Saint Vincent and the Grenadines, Samoa, Sao Tome and Principe, Senegal, Serbia, Sierra Leone, Sint Maarten, Slovakia, Slovenia, Solomon Islands, Somalia, South Africa, South Korea, South Sudan, Spain, Sri Lanka, St. Pierre and Miquelon, Sudan, Suriname, Sweden, Switzerland, Syria, Tajikistan, Tanzania, Thailand, Timor-Leste, Togo, Tonga, Tunisia, Türkiye, Turkmenistan, Tuvalu, Uganda, UK, Ukraine, Uzbekistan, Vanuatu, Venezuela, Vietnam, Wallis and Futuna, Yemen, Zambia, Zimbabwe
Date posted: Dec 12, 2025

Quick Summary

Objectives: 

Objectives

  • Purpose: Support the development of existing monoclonal antibody candidates for prevention and treatment of infections caused by one specified Flavivirus o...
Eligibility criteria: 
  • Eligible applicants: Any legal entity may participate, including entities from EU Member States, associated countries and other eligible third countries, subject to the call conditions. US legal entities are eligible to receive Union funding. Third-country participation is encouraged where viruses are endemic or outbreaks have occurred.
  • Geographic and legal eligibility: Entities established in China are not eligible. Entit...
Share

Similar grants

By Locations
Funding Agency: NGO
Status: open
Location: Ireland, UK
Funding Agency: EC
Status: open
Location: Cyprus
By Sectors
Funding Agency: Government
Status: open
Location: Norway
Funding Agency: NPO
Status: open
Location: UK